182 related articles for article (PubMed ID: 36152767)
1. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T
J Hepatol; 2023 Feb; 78(2):390-400. PubMed ID: 36152767
[TBL] [Abstract][Full Text] [Related]
2. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
[TBL] [Abstract][Full Text] [Related]
5. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
J Hepatol; 2024 Mar; ():. PubMed ID: 38479612
[TBL] [Abstract][Full Text] [Related]
6. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
Wong YJ; Zhaojin C; Tosetti G; Degasperi E; Sharma S; Agarwal S; Chuan L; Huak CY; Jia L; Xiaolong Q; Saraya A; Primignani M
Clin Mol Hepatol; 2023 Jan; 29(1):135-145. PubMed ID: 36064306
[TBL] [Abstract][Full Text] [Related]
7. [Risk factors of clinically significant portal hypertension in patients with compensated liver cirrhosis based on hepatic venous pressure gradient].
Jiang FR; Yan HD
Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):995-1000. PubMed ID: 34814395
[No Abstract] [Full Text] [Related]
8. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
[TBL] [Abstract][Full Text] [Related]
9. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
[TBL] [Abstract][Full Text] [Related]
10. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
Liu C; Li J; Wong YJ; Xie Q; Hirooka M; Enomoto H; Kim TH; Hanafy AS; He R; Koizumi Y; Hiasa Y; Nishimura T; Iijima H; Jung YK; Yim HJ; Ma J; Zeng QL; Sarin SK; Qi X
Hepatol Int; 2022 Oct; 16(5):1105-1115. PubMed ID: 35606627
[TBL] [Abstract][Full Text] [Related]
11. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.
Berzigotti A; Seijo S; Arena U; Abraldes JG; Vizzutti F; García-Pagán JC; Pinzani M; Bosch J
Gastroenterology; 2013 Jan; 144(1):102-111.e1. PubMed ID: 23058320
[TBL] [Abstract][Full Text] [Related]
12. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
Dallio M; Romeo M; Vaia P; Auletta S; Mammone S; Cipullo M; Sapio L; Ragone A; Niosi M; Naviglio S; Federico A
World J Gastroenterol; 2024 Feb; 30(7):685-704. PubMed ID: 38515952
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model.
Rabiee A; Deng Y; Ciarleglio M; Chan JL; Pons M; Genesca J; Garcia-Tsao G
Hepatol Commun; 2022 Dec; 6(12):3324-3334. PubMed ID: 36214066
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
[TBL] [Abstract][Full Text] [Related]
15. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: a prospective study.
Augustin S; Millán L; González A; Martell M; Gelabert A; Segarra A; Serres X; Esteban R; Genescà J
J Hepatol; 2014 Mar; 60(3):561-9. PubMed ID: 24211744
[TBL] [Abstract][Full Text] [Related]
16. Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension.
Semmler G; Hartl L; Mendoza YP; Simbrunner B; Jachs M; Balcar L; Schwarz M; Hofer BS; Fritz L; Schedlbauer A; Stopfer K; Neumayer D; Maurer J; Szymanski R; Meyer EL; Scheiner B; Quehenberger P; Trauner M; Aigner E; Berzigotti A; Reiberger T; Mandorfer M
Hepatology; 2024 Mar; ():. PubMed ID: 38447034
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnosis and follow-up of portal hypertension.
Thabut D; Weil D; Bouzbib C; Rudler M; Cassinotto C; Castéra L; Serste T; Oberti F; Ganne-Carrié N; de Lédinghen V; Bourlière M; Bureau C
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101767. PubMed ID: 34332128
[TBL] [Abstract][Full Text] [Related]
18. Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
Pastrovic F; Novak R; Grgurevic I; Hrkac S; Salai G; Zarak M; Grgurevic L
PLoS One; 2024; 19(4):e0301416. PubMed ID: 38603681
[TBL] [Abstract][Full Text] [Related]
19. MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension.
Kennedy P; Stocker D; Carbonell G; Said D; Bane O; Hectors S; Abboud G; Cuevas J; Bolster BD; Friedman SL; Lewis S; Schiano T; Bhattacharya D; Fischman A; Thung S; Taouli B
Eur Radiol; 2022 Dec; 32(12):8339-8349. PubMed ID: 35727321
[TBL] [Abstract][Full Text] [Related]
20. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.
Grgurevic I; Madir A; Trkulja V; Bozin T; Aralica G; Podrug K; Mikolaševic I; Tsochatzis E; O'Beirne J; Pinzani M
Eur J Clin Invest; 2022 Jun; 52(6):e13750. PubMed ID: 35040495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
